Pharma Foods International (TYO:2929) will establish Cadasil Drug Discovery Research Department in collaboration with the National Cerebral and Cardiovascular Center, according to a Wednesday filing on the Tokyo Stock Exchange.
Cadasil, a genetic vascular disease with no established cure, is linked to NOTCH3 gene mutations, leading to migraines, strokes, and dementia.
The National Cerebral and Cardiovascular Center, a research institute for cardiovascular diseases, is conducting Phase 2 clinical trials on adrenomedullin peptide as a potential treatment.
Pharma Foods will apply its expertise in peptide research to develop new therapies for the disease, aligning with its broader mission of advancing healthcare innovations.
Price (JPY): $940.00, Change: $-10, Percent Change: -1.05%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.